MERS, Ebola, bird flu: Science’s big missed opportunities

admin   •   October 27, 2015   •   2406

The gloved hands of an army nurse are seen during a demonstration of an isolation chamber for the treatment of infectious disease patients, at the Germany army medical centre, Bundeswehr Clinc, in Koblenz October 16, 2014. REUTERS/Ralph Orlowski

The gloved hands of an army nurse are seen during a demonstration of an isolation chamber for the treatment of infectious disease patients, at the Germany army medical centre, Bundeswehr Clinc, in Koblenz October 16, 2014. REUTERS/Ralph Orlowski

Anyone who goes down with flu in Europe this winter could be asked to enroll in a randomized clinical trial in which they will either be given a drug, which may or may not work, or standard advice to take bed rest and paracetamol.

Those who agree could be helping the world prepare for the next potentially deadly disease pandemic as well as helping scientists who are now desperate to plug gaps in knowledge left by previous missed opportunities.

Scientists are largely in the dark about how to stop or treat the slew of never-seen-before global health problems of recent years, from the emergence of the deadly MERS virus in Saudi Arabia, to a new killer strain of bird flu in China and an unprecedented Ebola outbreak in West Africa.

They have been unable even to pin down where they came from.

That is because vital studies to analyze transmission routes and test experimental drugs or vaccines have simply not been done during epidemics, disease experts say.

It is a failure of science, they say, that should not be allowed to happen again.

“Research in all of the epidemics we have faced over the past decade has been woeful,” said Jeremy Farrar, director of the Wellcome Trust global health foundation and an expert on infectious diseases. “The world is at risk because there are huge gaps in our knowledge base.

“We don’t now have a vaccine for SARS if it came back tomorrow; we don’t know how to treat MERS; it took us six to nine months before we started clinical trials of vaccines for Ebola and in the meantime almost 12,000 people lost their lives; and during the H1N1 pandemic, the number of people randomized into clinical studies was very close to zero.”


Bureaucracy, logistics and lack of forethought are the heart of the problem, according to Trudie Lang, professor of Global Health Research at Oxford University who has been working on ways to lower such barriers.

During the Ebola outbreak that swept through Guinea, Liberia and Sierra Leone, Lang’s team, which specializes in planning and operating trials in vulnerable populations in difficult settings, was tasked with setting up a clinical study of a potential Ebola treatment called brincidofovir.

“It normally takes 18 months to set up a trial, and we did it in 16 weeks,” she told Reuters. “But the problem was we were still behind the curve.”

In the 2009 H1N1 “swine flu” pandemic, when many governments had stockpiled antiviral drugs such as Roche’s (ROG.VX) Tamiflu and GlaxoSmithKline’s (GSK.L) Relenza and doctors prescribed them, often as a preventative measure without a confirmed diagnosis, no proper randomized clinical trials were conducted to find out for sure whether they helped.

This has left health officials with little or no concrete evidence on which to base treatment decisions when the next pandemic flu strain threatens the world.

“It is a huge pity we haven’t made the most of our opportunity to generate evidence,” said Chris Butler, a clinical professor at Cardiff University’s Institute of Primary Care & Public Health, who is now working on the European-wide winter flu trial he hopes will help plug the evidence gap.

There is little doubt that launching clinical trials in an outbreak is fraught with difficulty, partly because a new or rare strain of disease can infect so many and overwhelm health services and partly because there are many bureaucratic hurdles.

Lang’s team were awarded funds in September 2014 and by January 2015 were able to start the trial, but this coincided with a sharp drop in the number of patients with Ebola as the West Africa outbreak was beginning to plateau.

Scientists point to vast amounts of form filling, box ticking, contract drafting, committee meeting and agreement signing that are involved in setting up a clinical trial.

“There’s a huge industry around making triallists ‘walk through treacle’,” said Butler. “There’s a myriad of permissions needed. It’s a Byzantine process… which can take months.

“It gives me a headache just thinking about all the approvals” from ethics committees, sponsors, lawyers, research and development leaders and clinicians, he said.

Legal agreements are needed between the suppliers of the product — the experimental drug, vaccine or other intervention — and the people running the trial, the funder and hospitals, clinics or health centers where patients will be recruited.

In an infectious disease outbreak scenario, particularly a fast-moving one like with flu or Ebola, these legal issues can be compounded by competition for access to patients.

During the Ebola epidemic for example, Lang says, there were five or six different research groups seeking to set up and run clinical trials in the three most affected countries, each of which already had limited health systems that had been overwhelmed and crushed by the outbreak.

“It was ludicrous,” she told Reuters. “Because essentially we all had to fight over the same patients. It was like a land grab, and by that time the (new) cases were going down.”


Part of the threat of any disease outbreak, be it Ebola in Africa, the 2003 outbreak of Severe Acute Respiratory Syndrome (SARS) epidemic, Middle East Respiratory Syndrome (MERS) in Saudi Arabia or the new H7N9 bird flu in China, is the unknown.

Yet Lang and others say there is nothing to say the sorts of clinical trials needed in an epidemic cannot largely be drawn up, agreed, signed and sealed ahead of time.

“We need to have protocols ready to go, we need to have a task force of research staff in each region on standby to be deployed into the next outbreak trials,” she said.

Legal contracts, for instance, cover broadly the same things for any trial — data sharing and storage, patient confidentiality, informed consent, the timing and publication of results, and the pricing, production and availability of the product if and when it proves useful.

And in a rapidly moving outbreak which may be too swift and deadly to allow for months of organization, a coordinated approach would overcome the problem of having multiple research groups with not enough patients.

This would be both scientifically and ethically preferable, said Lang, since if a trial has to be stopped because it runs out of participants with the relevant disease, then everyone who has taken part until then has run a needless risk.

“The main issue is that this needs to be done in days rather than weeks or months,” she said. “That basically means research has to be embedded in the immediate response to an outbreak, and not come as an afterthought.”

(Reporting by Kate Kelland, editing by Timothy Heritage)

TAGS   , ,

DA confirms bird flu outbreak in Nueva Ecija

Marje Pelayo   •   March 16, 2020

MANILA, Philippines – The Department of Agriculture (DA) on Monday (March 16) announced an outbreak of bird flu or the H5N6 avian influenza in a quail farm in Jaen, Nueva Ecija.

Agriculture Secretary William Dar said some 1,500 quails in the said farm of Barangay Ulanin-Pitak in the said municipality after the Provincial Veterinary Office (PVO) confirmed the H5N6 cases in the area.

Luzon was hit by bird flu outbreak in 2017 but Dar said there were no reported cases of poultry to human transmissions in the country during that time.

According to DA, samples from 30 live quails from the said farm tested positive for the highly-contagious disease.

Following the announcement, the DA also imposed the one-kilometer radius quarantine protocol and the seven-kilometer surveillance zone.

“Surveillance around the 1-km and 7-km radius will be carried out immediately to ensure that the disease has not progressed around the said perimeter,” Dar said.

“Animal quarantine checkpoints have also been established to restrict the movement of all live domestic birds to and from the 1-km radius quarantine area,” he added.

Last Congo Ebola patient discharged with end of outbreak in sight

UNTV News   •   March 4, 2020

The last patient being treated for Ebola in Democratic Republic of Congo was discharged on Tuesday (March 3), the World Health Organization (WHO) said, bringing the 19-month-old outbreak closer than ever to an end.

Masika Semida’s release from hospital in the eastern city of Beni, feted by hospital staff who sang, danced and drummed, marks the first time there has been no active cases since the outbreak was declared in August 2018.

In that period, the virus has killed 2,264 people and infected nearly 1,200 more, making it the second-worst Ebola outbreak in history. Only the 2013-16 epidemic in West Africa was deadlier, killing more than 11,000.

Congo has now gone 14 days without any new confirmed cases. The outbreak can be declared over once 42 days have passed without a new case – equivalent to two cycles of 21 days, the maximum incubation period for the virus. (Reuters Connect)

(Production: Edwin Waita, Erikas Mwisi, Louisa Naks)

DA bans poultry products from Czech Republic due to H5N8 bird flu

Marje Pelayo   •   February 10, 2020

MANILA, Philippines — The Department of Agriculture (DA) on Friday (February 7) temporarily banned the entry of poultry and wild birds from the Czech Republic in a step to keep the Philippines free of the highly pathogenic H5N8.

DA Memorandum Order 13, Series of 2020, banned the importation of domestic and wild birds and their products from the Central European country after it declared an outbreak of the said highly pathogenic avian influenza (HPAI) specifically in Stepanov nad Svratkou, Zdar nad Sazavou, Vysocina.

The ban covers poultry products such as poultry meat, avian semen, day-old chicks, wild and domestic chicks.

Likewise, the DA also suspended all applications and evaluations of sanitary and phytosanitary import clearance to the banned products from Czech Republic.

All DA veterinary quarantine officers were ordered to stop all shipments of the said banned products at all major ports in the country.

Prior to the ban, the DA had ordered a temporary ban on the entry of wild birds and other poultry products from Poland also because of the H5N8 outbreak.


The Philippine Broadcast Hub

UNTV, 915 Barangay Philam,

EDSA, Quezon City M.M. 1104

(+632) 8396-8688 (Tel) (General inquiries)


UNTV is a major TV broadcast network with 24-hour programming. An Ultra High Frequency station with strong brand content that appeal to everyone, UNTV is one of the most trusted and successful Philippine networks that guarantees wholesome and quality viewing experience.